Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

YOU WONT BELIEVE: Ctlt - What They Never Told You

Eli Lilly (LLY) vs. Catalent (CTLT): Which Pharma Stock Offers Better Returns?

The pharma industry is evolving rapidly due to the ever-rising healthcare needs and increasing demand for customized medicine and treatments worldwide. So, let’s analyze Eli Lilly (LLY) and Catalent (CTLT), to determine which pharma stock offers better returns. Read more.

Catalent Stock: Analyst Estimates & Ratings

Catalent Stock: Analyst Estimates & Ratings

Despite Catalent’s outperformance relative to the broader market over the past year, Wall Street analysts remain cautious about the stock’s prospects.

What to Expect From Catalent's Next Quarterly Earnings Report

What to Expect From Catalent's Next Quarterly Earnings Report

Catalent is expected to release its first-quarter earnings next month, and analysts expect a triple-digit profit surge.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Catalent Stock: Is CTLT Outperforming the Healthcare Sector?

Despite Catalent’s outperformance relative to the broader sector, Wall Street analysts remain cautious about the stock’s prospects.

Do Wall Street Analysts Like Catalent Stock?

While Catalent has outperformed the broader market over the past year, analysts are cautious about the stock’s potential.

What to Expect From Catalent's Q4 2024 Earnings Report

Catalent will unveil its Q4 earnings in September, and analysts project a triple-digit bottom-line growth.

Catalent (CTLT) Loses 6.1% Over the Past Month: Can the Stock Reverse Its Fortune?

Catalent, Inc. (CTLT) recently faced a setback, witnessing a 6.1% dip in its stock value over the last month. However, in the light of the recent release of its first quarter results of fiscal 2024, can the company reverse its fortune? Keep reading….

inkl

Read news from The Economist, FT, and more,
with one subscription

Stocks Set to Open Lower as Investors Await FOMC Minutes, U.S. Debt-Ceiling Talks in Focus

Stocks Set to Open Lower as Investors Await FOMC Minutes, U.S. Debt-Ceiling Talks in Focus

June S&P 500 futures (ESM23) are down -0.03%, and June Nasdaq 100 E-Mini futures (NQM23) are down -0.14% this morning as market participants continued to monitor U.S. debt-ceiling negotiations while awaiting the release of the Fed’s favorite inflation gauge and the minutes of the Federal Reserve’s latest policy meeting.

Stocks Set to Open Mixed as Investors Await FOMC Minutes, U.S. Debt-Ceiling Talks in Focus

Stocks Set to Open Mixed as Investors Await FOMC Minutes, U.S. Debt-Ceiling Talks in Focus

June S&P 500 futures (ESM23) are down -0.03%, and June Nasdaq 100 E-Mini futures (NQM23) are up +0.01% this morning as market participants continued to monitor U.S. debt-ceiling negotiations while awaiting the release of the Fed’s favorite inflation gauge and the minutes of the Federal Reserve’s latest policy meeting.

Morgan Stanley Maintains Overweight Rating for Catalent: Here's What You Need To Know

Morgan Stanley Maintains Overweight Rating for Catalent: Here's What You Need To Know

Morgan Stanley has decided to maintain its Overweight rating of Catalent (NYSE:CTLT) and lower its price target from $145.00 to $132.00. Shares of Catalent are trading up 1.11% over the last 24 hours, at $101.06 per share. A move to $132.00 would account for a 30.62% increase from the current…

Catalent Shares Jump As Investors Cheer Revised, Better Than Expected FY22 Outlook

Catalent Shares Jump As Investors Cheer Revised, Better Than Expected FY22 Outlook

Catalent Inc (NYSE:CTLT) reported Q3 FY22 sales of $1.27 billion, +21% Y/Y as reported, or 23% in constant currency, edging out analysts' average expectation of $1.22 billion. Adjusted EPS of $1.04, compared to $0.82 last year, surpassed the consensus of $0.94. Adjusted EBITDA was $339 million, or a margin of 27%, compared…

Recap: Catalent Q3 Earnings

Recap: Catalent Q3 Earnings

Catalent (NYSE:CTLT) reported its Q3 earnings results on Tuesday, May 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

How To Attend Catalent Q3 2022 Earnings Conference Call

How To Attend Catalent Q3 2022 Earnings Conference Call

Catalent (NYSE:CTLT) will host a conference call at 08:15 AM ET on May 3, 2022, to discuss Q3 2022 earnings results. How to Attend Catalent (CTLT) Conference Call Follow this link to access the live webcast.

3 Large-Cap Healthcare Stocks with More Than 40% Upside, According to Wall Street

3 Large-Cap Healthcare Stocks with More Than 40% Upside, According to Wall Street

The healthcare industry is growing rapidly on increasing demand and continuing advancements in therapies. Furthermore, this year is expected to be a transformative one for the healthcare sector, with a more robust transition to digital health. Given the industry's growth potential, Wall Street analysts see more than 40% potential upside…

Get all your
news in one place.

100's of premium titles.
One news app.

Catalent's Q2 Earnings Beat Street View, Lifts FY22 Guidance

Catalent Inc (NYSE: CTLT) has reported Q2 FY22 sales of $1.

Earnings Outlook For Catalent

Catalent (NYSE:CTLT) is set to give its latest quarterly earnings report on Tuesday, 2022-02-01. Here's what investors need to know before the announcement. Analysts estimate that Catalent will likely report an Earnings Per Share (EPS) of $0.83.

A Bearish Sign Appears On Catalent's Chart

If history is any guide, there may be trouble ahead for shares of Catalent (NYSE:CTLT). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

Expert Ratings For Catalent

Analysts have provided the following ratings for Catalent (NYSE:CTLT) within the last quarter:

Get all your
news in one place.

100's of premium titles.
One news app.

1

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

the Federal Reserve

Medical Pharmaceuticals

Eli Lilly and Company

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

366,308 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play